Compare Abeona Therapeutics Inc (ABEO) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Domino's Pizza, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.5 (market cap $421.19M), while Domino's Pizza, Inc. trades at $353.56 (market cap $11.82B). The key difference: Domino's Pizza, Inc. is far larger — about 28.1× Abeona Therapeutics Inc's market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DPZ | |
|---|---|---|
Market Cap | $421.19M | $11.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $467.30 |
52-Week Low | $4.17 | $282.89 |
Enterprise Value | $276.10M | $16.78B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
DPZ trades at $353.57, up 1.64% today, with bullish technical signals from moving averages and a consensus analyst price target of $371.67. Recent earnings missed expectations in Q2 2026, but revenue grew to $4.94B in 2025 with a net income margin of 11.86%. The company launched a new individual-size pizza in August 2026 to boost sales, while high debt levels and weak premium pizza demand pose challenges.
The outlook is cautiously optimistic, supported by analyst buy ratings (53.85%) and innovation initiatives, but risks include rising input costs, competitive pressures, and insider selling. Investors should weigh strong cash flow generation against debt sustainability for long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
